Cancer Therapy Doesn't Diminish Vaccine Efficacy

Patients with cancer are at high risk for complications and death from COVID-19 infections, but vaccination offers patients with solid tumors strong protection against SARS-CoV-2, including the Delta variant. Patients with hematologic malignancies, however, are less likely to mount a strong immune response to vaccination, possibly due to the natural history of the disease and to B cell–depleting therapies that affect antibody responses.